Hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitors induce autophagy and have a protective effect in an in-vitro ischaemia model
- Sci Rep. 2020 Jan 31;10(1):1597. doi: 10.1038/s41598-020-58482-w.
- 1. Institute for Science and Technology in Medicine, School of Pharmacy, Keele University, Newcastle under Lyme, Staffordshire, ST5 5BG, United Kingdom.
- 2. Chemistry Research Laboratory, Department of Chemistry, University of Oxford, Oxford, OX1 5JJ, United Kingdom.
- 3. Institute for Science and Technology in Medicine, School of Pharmacy, Keele University, Newcastle under Lyme, Staffordshire, ST5 5BG, United Kingdom. [email protected].
This study compared effects of five hypoxia-inducible factor (HIF) prolyl hydroxylases (PHD) inhibitors on PC12 cells and primary rat neurons following oxygen-glucose deprivation (OGD). At 100 µM, the PHD inhibitors did not cause cytotoxicity and Apoptosis. MTT activity was only significantly reduced by FG4592 or Bayer 85-3934 in PC12 cells. The PHD inhibitors at 100 µM significantly increased the LC3-II/LC3-I expression ratio and downregulated p62 in PC12 cells, so did FG4592 (30 µM) and DMOG (100 µM) in neurons. HIF-1α was stabilised in PC12 cells by all the PHD inhibitors at 100 µM except for DMOG, which stabilised HIF-1α at 1 and 2 mM. In primary neurons, HIF-1α was stabilised by FG4592 (30 µM) and DMOG (100 µM). Pretreatment with the PHD inhibitors 24 hours followed by 24 hour reoxygenation prior to 6 hours OGD (0.3% O2) significantly reduced LDH release and increased MTT activity compared to vehicle (1% DMSO) pretreatment. In conclusion, the PHD inhibitors stabilise HIF-1α in normoxia, induce Autophagy, and protect cells from a subsequent OGD insult. The new class of PHD inhibitors (FG4592, FG2216, GSK1278863, Bay85-3934) have the higher potency than DMOG. The interplay between Autophagy, HIF stabilisation and neuroprotection in ischaemic stroke merits further investigation.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
Research Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cardiovascular Disease